Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Short description of key information on bioaccumulation potential result: 
From the study it is clear that DADPM/DEG-PO does undergo biotransformation in incubations with human liver microsomes indicating metabolism and no possible bioaccumolation potential.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information

The metabolism of DADPM/DEG-PO was investigated using human liver microsomes. DADPM/DEG-PO (50 and 200 mg/L) was incubated with pooled human liver microsomes (0.5 and 2.0 mg/mL), pre-treated with alamethicin and in the presence of NADPH and UDPGA, for up to 120 minutes. The LC-MS analysis of the human liver microsome incubation samples was carried out. From the result shows that the test compound mixture (DADPM/DEG-PO) undergoes biotransformation in incubations with human liver microsomes pre-treated with alamethicin to enable access of substrates to the UGT active site and in the presence of the enzyme cofactors NADPH (for oxidative metabolism) and UDPGA (for glucuronic acid conjugation), as far as the aromatic components in the mixture are concerned. The data derived from the 2 hour incubations at both microsomal protein concentrations show the presence of glucuronide conjugates of the main aromatic components of the test compound mixture.